Cisplatin induces differentiation of breast cancer cells

Frontiers in Oncology

Volumn 3 JUN, Issue , 2013, Pages

  Prabhakaran, Praseetha ^a,b   Hassiotou, Foteini ^a   Blancafort, Pilar ^a   Filgueira, Luis ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITI TEKNOLOGI MALAYSIA   (Malaysia)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Breast cancer cells; Cancer stem cells; Cisplatin; Differentiation; Proliferation

Indexed keywords

ALPHA6 INTEGRIN; BETA TUBULIN; CISPLATIN; CYTOKERATIN 18; NESTIN; SMOOTH MUSCLE ACTIN; STAGE SPECIFIC EMBRYO ANTIGEN 4;

ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE TEST; LOW DRUG DOSE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84891599743     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00134     Document Type: Article

References (49)

1. Al-Ejeh, F., Smart, C. E., Morrison, B. J., Chenevix-Trench, G., López, J. A., Lakhani, S. R., et al. (2011). Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32, 650-658. doi:10.1093/carcin/bgr028.
2. Basu, A., and Krishnamurthy, S. (2010). Cellular responses to Cisplatin-induced DNA damage. J. Nucleic Acids 2010, pii: 201367. doi:10.4061/2010/201367.
3. Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R., and Lluch, A. (2010). Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat. Rev. 36, 206-215. doi:10.1016/j.ctrv.2009.12.002.
4. Byrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., et al. (2012). Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 14, R110. doi:10.1186/bcr3231.
5. Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., and Pérez, J. M. (2007). Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem. 7, 3-8. doi:10.2174/187152007779314044.
6. Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H., Jones, D. L., et al. (2006). Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339-9344. doi:10.1158/0008-5472.CAN-06-3126.
7. Croker, A. K., and Allan, A. L. (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell. Mol. Med. 12, 374-390. doi:10.1111/j.1582-4934.2007.00211.x.
8. Dave, B., Mittal, V., Tan, N. M., and Chang, J. C. (2012). Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 14, 202. doi:10.1186/bcr2938.
9. Dickson, M. A., Carvajal, R. D., Merrill, A. H. Jr., Gonen, M., Cane, L. M., and Schwartz, G. K. (2011). A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res. 17, 2484-2492. doi:10.1158/1078-0432.CCR-10-2323.
10. Florea, A., and Busselberg, D. (2011). Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351-1371. doi:10.3390/cancers3011351.
11. Foroodi, F., Duivenvoorden, W. C., and Singh, G. (2009). Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Anticancer Drugs 20, 115-122. doi:10.1097/CAD.0b013e32831c14ec.
12. Hadnagy, A., Beaulieu, R., and Balicki, D. (2008). Histone tail modifications and non-canonical functions of histones: perspectives in cancer epigenetics. Mol. Cancer Ther. 7, 740-748. doi:10.1158/1535-7163.MCT-07-2284.
13. Hassiotou, F., Beltran, B., Chetwynd, E., Stuebe, M., Twigger, A. J., Metzger, P., et al. (2012). Breast milk is a novel source of stem cell with multilineage differentiation potential. Stem Cells 30, 2164-2174. doi:10.1002/stem.1188.
14. Hassiotou, F., and Geddes, D. (2012). Anatomy of the human mammary gland: current status of knowledge. Clin. Anat. 26, 29-48. doi:10.1002/ca.22165.
15. Hassiotou, F., Geddes, D. T., and Hartmann, P. E. (2013a). Cells in human milk: state of the science. J. Hum. Lact. 29, 171-182. doi:10.1177/0890334413477242.
16. Hassiotou, F., Hepworth, A., Beltran, A., Mathews, M., Stuebe, A., Hartmann, P. E., et al. (2013b). Expression of the pluripotency transcription factor OCT4 in the normal and aberrant mammary gland. Front. Oncol. 3:79. doi:10.3389/fonc.2013.00079.
17. Hastak, K., Alli, E., and Ford, J. M. (2010). Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 70, 7970-7980. doi:10.1158/0008-5472.CAN-09-4521.
18. Hergueta-Redondo, M., Palacios, J., Cano, A., and Moreno-Bueno, G. (2008). "New" molecular taxonomy in breast cancer. Clin. Transl. Oncol. 10, 777-785. doi:10.1007/s12094-008-0290-x.
19. Holliday, D. L., and Speirs, V. (2011). Choosing the right cell line for breast cancer research. Breast Cancer Res. 13, 215. doi:10.1186/bcr2889.
20. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300. doi:10.3322/caac.20073.
21. Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E., and Lokshin, A. E. (2008). Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 3:e3077. doi:10.1371/journal.pone.0003077.
22. Meyer, M. J., Fleming, J. M., Lin, A. F., Hussnain, S. A., Ginsburg, E., and Vonderhaar, B. K. (2010). CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 70, 4624-4633. doi:10.1158/1538-7445.AM10-4577.
23. Milrot, E., Jackman, A., Flescher, E., Gonen, P., Kelson, I., Keisari, Y., et al. (2012). Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation. Invest. New Drugs 31, 333-344. doi:10.1007/s10637-012-9870-2.
24. Monteiro, J., and Fodde, R. (2010). Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur. J. Cancer 46, 1198-1203. doi:10.1016/j.ejca.2010.02.030.
25. Nakshatri, H., Srour, E. F., and Badve, S. (2009). Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. Ther. 4, 50-60. doi:10.2174/157488809787169110.
26. Nguyen, N. P., Almeida, F. S., Chi, A., Nguyen, L. M., Cohen, D., Karlsson, U., et al. (2010). Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat. Rev. 36, 485-491. doi:10.1016/j.ctrv.2010.02.016.
27. Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., et al. (2003). Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 63, 8977-8983.
28. Perou, C. M. (2011). Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl. 1), 61-70. doi:10.1634/theoncologist.2011-S1-61.
29. Pines, A., Kelstrup, C. D., Vrouwe, M. G., Puigvert, J. C., Typas, D., Misovic, B., et al. (2011). Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells. Mol. Cell. Biol. 31, 4964-4977. doi:10.1128/MCB.05258-11.
30. Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., et al. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68. doi:10.1186/bcr2635.
31. Rosenberg, B., Vancamp, L., and Krigas, T. (1965). Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699. doi:10.1038/205698a0.
32. Rosenberg, B., VanCamp, L., Trosko, J. E., and Mansour, V. H. (1969). Platinum compounds: a new class of potent antitumour agents. Nature 222, 385-386. doi:10.1038/222385a0.
33. Sampieri, K., and Fodde, R. (2012). Cancer stem cells and metastasis. Semin. Cancer Biol. 22, 187-193. doi:10.1016/j.semcancer.2012.03.002.
34. Sanges, D., and Cosma, M. P. (2010). Reprogramming cell fate to pluripotency: the decision-making signalling pathways. Int. J. Dev. Biol. 54, 1575-1587. doi:10.1387/ijdb.103190ds.
35. Shafee, N., Smith, C. R., Wei, S., Kim, Y., Mills, G. B., Hortobagyi, G. N., et al. (2008). Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243-3250. doi:10.1158/0008-5472.CAN-07-5480.
36. Short, J. J., and Curiel, D. T. (2009). Oncolytic adenoviruses targeted to cancer stem cells. Mol. Cancer Ther. 8, 2096-2102. doi:10.1158/1535-7163.MCT-09-0367.
37. Sotiriou, C., and Pusztai, L. (2009). Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800. doi:10.1056/NEJMra0801289.
38. Stagg, J., and Pommey, S. (2009). Properties of mesenchymal stem cells to consider for cancer cell therapy. Stem Cell Biol. Health Dis. 79-97. doi:10.1007/978-90-481-3040-5_5.
39. Tiwary, R., Yu, W., Sanders, B. G., and Kline, K. (2011). Alpha-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res. 13, R1. doi:10.1186/bcr2801.
40. Turashvili, G., Bouchal, J., Baumforth, K., Wei, W., Dziechciarkova, M., Ehrmann, J., et al. (2007). Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55. doi:10.1186/1471-2407-7-55.
41. Villadsen, R., Fridriksdottir, A. J., Rønnov-Jessen, L., Gudjonsson, T., Rank, F., LaBarge, M. A., et al. (2007). Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol. 177, 87-101. doi:10.1083/jcb.200611114.
42. Visvader, J. E. (2009). Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 23, 2563-2577. doi:10.1101/gad.1849509.
43. Wang, Q., Milum, K., Han, C., Huang, Y. W., Wani, G., Thomale, J., et al. (2011). Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol. Cancer 10, doi:10.1186/1476-4598-10-24.
44. Wexselblatt, E., Eylon, Y., and Gibson, D. (2012). Cellular interaction of platinum drugs. Inorganica Chim. Acta 393, 75-83. doi:10.1016/j.ica.2012.07.013.
45. Wicha, M. S., Liu, S., and Dontu, G. (2006). Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 66, 1883-1890; discussion 1895-1886. doi:10.1158/0008-5472.CAN-05-3153.
46. Woelfle, U., Sauter, G., Santjer, S., Brakenhoff, R., and Pantel, K. (2004). Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin. Cancer Res. 10, 2670-2674. doi:10.1158/1078-0432.CCR-03-0114.
47. Zeidan, Y. H., Jenkins, R. W., and Hannun, Y. A. (2008). Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J. Cell Biol. 181, 335-350. doi:10.1083/jcb.200705060.
48. Zhao, Y., Bao, Q., Renner, A., Camaj, P., Eichhorn, M., Ischenko, I., et al. (2011). Cancer stem cells and angiogenesis. Int. J. Dev. Biol. 55, 477-482. doi:10.1387/ijdb.103225yz.
49. Zhou, B. B., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., and Dirks, P. B. (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806-823. doi:10.1038/nrd2137.